 CAMBRIDGE, Mass., Sept. 01, 2022 GLOBE NEWSWIRE -- Foghorn Therapeutics Inc. Nasdaq: FHTX, a clinical stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene expression, today announced managements participation in upcoming investor conferences in September. With an initial focus in oncology, Foghorns Gene Traffic Control Platform and resulting broad pipeline have the potential to transform the lives of people suffering from a wide spectrum of diseases. 